104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants

Assessment of Safety and Efficacy of BG9924 in Subjects With RA Who Have Participated in Study 104RA202.

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00664573

Acronym

RESPOND-EXT

Enrollment

339

Registered

2008-04-23

Start date

2007-11-30

Completion date

2008-10-31

Last updated

2016-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

Safety, Rheumatoid Arthritis, Baminercept alfa, Methotrexate, BG9924, Efficacy

Brief summary

To observe the long-term treatment with BG9924 when administered to participants with RA who previously participated in a Biogen Idec Study.

Interventions

BIOLOGICALBaminercept alfa (BG9924)

dosage administered as per Biogen-Idec protocol

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Must be a participant from Study 104RA202 (NCT 00664716) * Stable dose of Methotrexate for the duration of the study

Exclusion criteria

* Participants with a significant change in their medical history from their previous BG9924 study * Any clinically significant infectious illness or serious local infection NOTE: Other protocol defined Inclusion/

Design outcomes

Primary

Measure	Time frame
To Observe The Long-Term treatment with BG9924 When Administered to Participants with RA who Previously Participated in a Biogen Idec Study	Duration of this study is 18 months

Countries

Argentina, Brazil, Hungary, Mexico, Poland, Romania, Russia, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026